Anti-Ebolavirus (GP protein specific; Base region-specific) [Clone EBOV-520] — Purified No Carrier Protein

Sequenced from PBMCs from a donor who had recovered from a naturally-occurring EBOV infection.

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EBOV-520 activity is directed against the base region, GP1/GP2 junction; recognizes cleaved GP subunit of Zaire ebolavirus (EBOV) and Bundibugyo ebolavirus (BDBV) glycoprotein.

Pan-Ebolavirus Neutralizing Monoclonal Antibody (EBOV-520)

Ebolavirus Pathogenesis and Glycoprotein (GP) Structure
Ebola virus is a member of the Filoviridae family that causes severe, often fatal hemorrhagic fever in humans, with mortality rates ranging from 25% to 90%1. Three distinct ebolavirus species are primarily responsible for lethal human outbreaks: Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Sudan ebolavirus (SUDV).

The ebolavirus envelope features a single surface glycoprotein (GP trimer) that mediates host cell attachment, endosomal entry, and membrane fusion1. The GP monomer is divided into two major subunits:

GP1: Contains a heavily glycosylated mucin-like domain (MLD) and a protective glycan cap.

GP2: Houses the internal fusion loop, transmembrane domain, and stalk region.

Because of its critical role in viral entry, the ebolavirus glycoprotein is the primary target for vaccine design and therapeutic neutralizing monoclonal antibodies (mAbs).^1,2,3,4

EBOV-520: A Broadly Neutralizing Base-Region Antibody

EBOV-520 is a highly conserved, pan-ebolavirus neutralizing monoclonal antibody originally isolated from human peripheral blood mononuclear cells (PBMCs) of a survivor of the 2013–2016 EBOV outbreak.² Memory B cells reactive to ebolavirus GP were isolated using fluorescently labeled recombinant protein, purified via FACS, bulk-expanded, and fused with MFP-2 myeloma cells to generate stable hybridomas.

Unlike traditional strain-specific antibodies, EBOV-520 is a rare, high-value tool that targets a highly conserved site of vulnerability at the GP1/GP2 junction (base region).

Cross-Species Neutralization: Demonstrates functional neutralizing activity against all three clinically important ebolaviruses: EBOV, BDBV, and SUDV.^2,4

Cleaved GP Recognition: Uniquely recognizes both intact and endosomally cleaved GP, allowing it to directly block the viral fusion machinery during host cell entry.

Applications: Highly optimized for vaccine benchmarking, recombinant antigen quality control (QC), and serum competition assays to track immune convergence on cross-protective base epitopes.

Ebola virus glycoprotein is a surface protein expressed on the virus envelope.

Synergistic Mechanisms & Two-Antibody Cocktail Potential

EBOV-520 was identified alongside EBOV-548 (a glycan-cap-binding mAb) as part of a cooperative, multi-mechanistic two-antibody cocktail^1,2,4. When paired, EBOV-520 and EBOV-548 exhibit strong synergistic activity for both GP binding and viral neutralization^1,2. This cooperative effect is concentration-dependent and driven by distinct mechanical alterations:

In vivo efficacy data underscores this synergy: When evaluated against the highly divergent Sudan ebolavirus (SUDV), monotherapy with EBOV-520 yields a 10% survival rate in mouse models. However, when co-administered with EBOV-548, protection is potently potentiated, increasing the overall survival rate to 50%^1,2.

1 Gilchuk, P., et al. (2018). Multifunctional Pan-Ebolavirus Antibody Cocktails Synergistically Protect Non-human Primates. Immunity, 49(3), 521-533
2 Gilchuk P, Murin CD, Milligan JC, et al. Immunity. 52(2):388-403.e12. 2020.
3 Saphire EO, Aman MJ. Trends Microbiol. 24(9):684-686. 2016.
4 Murin CD, Gilchuk P, Ilinykh PA, et al. Cell Rep. 35(2):108984. 2021.